The Chile Pharmaceuticals and Healthcare Report

    • Independent 5-year pharmaceutical and healthcare industry forecasts for Chile.
    • Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Chilean pharmaceutical and healthcare industry.
    • Competitive intelligence, Chilean pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Chilean market.

The Chile Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2012 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Chile Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Chilean pharmaceutical and healthcare industry.

" “As we develop our business throughout Latin America, we have found BMI’s Pharmaceuticals & Healthcare Reports to be helpful and informative.” "
Royal Hanson, CEO Hanson Research Corp., USA

Key Benefits of Report

    • Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Chile to test other views – a key input for successful budgeting and strategic business planning in the Chilean pharmaceutical and healthcare market.
    • Target Business Opportunities & Risks in the Chilean Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Chile.
    • Exploit The Latest Competitive Chilean Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Chile.

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

  • Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
  • Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
  • OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
  • Generics market (US$bn)/ as % of total market
  • Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Executive Summary

[TOP]

Executive Summary

BMI has updated its 2006 Chilean pharmaceutical market figure to US$989mn in final consumer prices, based on several market sources. This is somewhat higher than the previous estimate and translates into 8.75% local currency growth and 10.5% US dollar growth. BMI has also upgraded its five-year market forecast somewhat, seeing a five-year 2006 to 2011 average annual growth rate of 6.4% per annum, compared to an earlier 5.5% annual growth estimate. In 2007, the market is now expected to reach a market value of US$1.05bn, representing 7.7% year-on-year growth and a value of US$1.35bn by 2011.

The government of President Michelle Bachelet has increased social spending, including a major expansion of the AUGE plan this year. Still, the government has become the focus of street protests by the country's largest union representing both public and private-sector workers and strikes by health workers, including the key doctor's organisation, the Medical College. Bachelet's government is arguably at a low point since taking office in March 2006. With record copper prices, she is under pressure from the left to further increase social spending while trying to keep a lid on inflation and spending. In the last months of 2007, the government will be looking for some concrete results and to announce new initiatives to calm social tensions.

Increased spending also means continued wrangling over stronger regulation and market protections for makers of patented drugs. Despite its liberal economic credentials, Chile's intellectual property (IP) environment remains problematic, although there are continued signs of forward progress. In May 2007, the government announced that it was making substantial progress on a tougher anti-piracy law, due to be ready at the end of the year. Measures reportedly include modifications to the country's patent law to close loopholes. Crucially, the government is said to be planning to launch an independent patent office, INAPI, to replace the current Intellectual Property Department.

For local players, the seeming inevitability that tougher rules will eventually prevail presents the challenge of meeting GMP requirements by next year. It also means finding new markets. In September, Laboratorios Andrómaco reportedly signed a deal to acquire three smaller Colombian producers, California, Memphis Products and Psipharma, further boosting its regional penetration. Closer to home, market leading retailer Farmacias Ahumada (FASA) launched a discount generics programme and vowed to capture 32% of the market by the end of 2007. Along with a US$100mn tie-up with developer Grupo Euroamérica to develop new locations, FASA's aggressive moves could spark a renewed pricing war as rivals Salcobrand – now under new ownership – and Cruz Verde look to defend their market positions. Intriguingly, Congress is reportedly looking at legislation that would liberalise over-the-counter drug sales, a move that could significantly open the market.

Contents

[TOP]

Chapter 1 - Executive Summary

Chile Pharmaceuticals & Healthcare Industry SWOT

Chapter 2 - Chile: Business Environment Ranking

Business Environment Ranking

Economics – Long-term Risk

Politics – Long-term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Chile: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property

National Formulary

Pricing & Reimbursement Issues

Chapter 5 - Industry Developments

Healthcare Sector

Recent Legislative Initiatives

Pharmaceutical Sector

Table - Latin American Regulations on Bioequivalence and GMP

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: Chile Drug Market Expenditure Forecasts 2005-2009

Key Growth Factors – Industry

Table: Chile Health Expenditure Forecasts 2005-2010

Key Growth Factors – Macroeconomic

Table: Economic Activity – Historical Data And Forecasts

Prescription Market Forecast

Table: Chile Prescription Market Forecasts 2004-2010

OTC Market Forecast

Table: Chile OTC Market Forecasts 2004-2010

Generics Market Forecast

Table: Generics And Branded Market Indicators

Export/Import Forecast

Table: Chile Pharmaceuticals Exports & Imports Forecasts 2005-2009

Key Risks To BMI’s Forecast Scenario

Chapter 7 - Competitive Landscape

Manufacturing Sector

Retail Sector

Chapter 8 - Company Monitor

Profiles

LabChile

Laboratorios Andrómaco

Laboratorios Maver

Chapter 9 - Latin America: Regional Market Overview

Chapter 10 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Chapter 11 - Appendix: Regional Demographic Data

Wages (ave per annum), US$

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Section 1: Population

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Competitive Landscape for Latin America Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of Latin American Pharmaceuticals & Healthcare Sources

[TOP]

BMI's Latin American Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceuticals industry associations, chambers of commerce and company reports. Information sources include:

 

Read about our other Pharmaceuticals & Healthcare Reports

Asia Europe Middle East & Africa Latin America
UK
UAE
[top]

 

Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 24 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.